Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

White Wine or Nutritional Supplement in Improving Appetite in Patients With Cancer

This study is ongoing, but not recruiting participants.
Information provided by:
Mayo Clinic Identifier:
First received: July 6, 2009
Last updated: March 24, 2014
Last verified: March 2014

RATIONALE: It is not yet know whether white wine is more effective than a nutritional supplement in improving appetite.

PURPOSE: This randomized clinical trial is studying white wine to see how well it works compared with a nutritional supplement in improving appetite in patients with cancer

Condition Intervention
Unspecified Adult Solid Tumor, Protocol Specific
Other: therapeutic nutritional supplementation
Dietary Supplement: white wine
Other: questionnaire administration

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Official Title: White Wine for Appetite Loss: A Randomized, Controlled, Non-Blinded Trial

Resource links provided by NLM:

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • Difference in the percentage of patients who report an improvement in their appetite over the intervention period [ Time Frame: First 3 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Differences in the percentage of patients who manifest weight stability, defined as weight gain of at least 5% of baseline [ Time Frame: At one month ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: Every 6 months for 2 years ] [ Designated as safety issue: No ]
  • Incidence of study intervention-related toxicity [ Time Frame: Prior to registration and at week 3-4 ] [ Designated as safety issue: Yes ]
  • Patient-reported quality of life (QOL) as measured by the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) appetite scale [ Time Frame: Prior to study intervention and then weekly ] [ Designated as safety issue: No ]

Estimated Enrollment: 140
Study Start Date: July 2009
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A (white wine)
Patients consume white wine twice daily for 3-4 weeks.
Dietary Supplement: white wine
Given orally
Other: questionnaire administration
Ancillary studies
Active Comparator: Arm B (non-wine nutritional supplement)
Patients receive an oral non-wine nutritional supplement (e.g., Boost or Ensure) twice daily for 3-4 weeks.
Other: therapeutic nutritional supplementation
Given orally
Other: questionnaire administration
Ancillary studies

Detailed Description:


I. To compare white wine (Arm A) to non-wine nutritional supplement (Arm B) for the treatment of cancer-associated anorexia.

II. To evaluate the side effect profile of white wine (Arm A).

OUTLINE: Patients are stratified according to primary malignant disease (lung vs gastrointestinal vs other [specify]), severity of weight loss (excluding peri-operative weight loss) within the past 2 months (< 4.6 kg [< 10 lbs] vs >= 4.6 kg [>= 10 lbs]), age (< 50 years vs >= 50 years), and planned concurrent chemotherapy or radiation (yes vs no).

Patients are randomized to 1 of 2 arms.

ARM A: Patients consume white wine with =< 15% alcohol content twice daily for 3-4 weeks.

ARM B: Patients receive an oral non-wine nutritional supplement (e.g., Boost or Ensure) twice daily for 3-4 weeks.

After completion of study treatment, patients are followed up every 6 months for 2 years.


Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Incurable, invasive malignancy
  • Able to reliably take the study intervention as prescribed in this protocol
  • No prior or current history of alcoholism
  • Alert and mentally competent
  • Physician estimates that patient has lost >= 5 pounds (2.3 kg) in weight =< 2 months (excluding peri-operative weight loss; documented weight loss not required) and/or have estimated caloric intake of < 20 cal/kg daily (no further documentation necessary other than an affirmative answer to this statement)
  • Patient perceives loss of appetite and/or weight as a problem; NOTE: Documentation not necessary
  • Concurrent chemotherapy and/or radiotherapy are permitted
  • Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
  • Willingness to abstain completely from alcohol for 4 weeks, except as prescribed in this trial; NOTE: Patients assigned to the non-wine nutritional supplement (Arm B) must be willing to abstain from wine and other alcoholic beverages for 3-4 weeks; Patients assigned to the white wine (Arm A) are allowed to take a nutritional supplement, such as Ensure or Boost if they choose to
  • Ability to complete questionnaire(s) by themselves or with assistance
  • Willingness to return to MCCRC enrolling institution for follow-up
  • Patients in whom the use of progestational agents is anticipated are not permitted to be on this study
  • Short-term use of dexamethasone around days of intravenous chemotherapy is allowed for protection against emesis, but dexamethasone for appetite stimulation is not permitted

Exclusion Criteria:

  • Receiving tube feedings or parenteral nutrition
  • Current (=< 1 month) or planned treatment with adrenal corticosteroids (short-term use of dexamethasone around days of chemotherapy is allowed for protection against emesis), androgens, or progestational agents; EXCEPTION: Inhalant, topical, or optical steroid use is permissible
  • Progestational agent (such as megestrol acetate) planned to be initiated over the next 30 days; NOTE: Patients who have been on megestrol acetate for > 1 month and are still on it and otherwise meet the eligibility criteria are permitted to enroll on this protocol and remain on megestrol acetate
  • Known mechanical obstruction of the alimentary tract, malabsorption, or intractable vomiting (> 5 episodes/week)
  • Symptomatic or untreated brain metastases
  • Any of the following as this regimen may be harmful to a developing fetus or nursing child: pregnant women, nursing women, and men or women of childbearing potential who are unwilling to employ adequate contraception
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00936728

United States, Arizona
Mayo Clinic in Arizona
Scottsdale, Arizona, United States
United States, Florida
Mayo Clinic in Florida
Jacksonville, Florida, United States
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, Pennsylvania
Geisinger Medical Center
Danville, Pennsylvania, United States, 17822-2001
Sponsors and Collaborators
Mayo Clinic
Study Chair: Aminah Jatoi, M.D. Mayo Clinic
Principal Investigator: Tom R. Fitch, M.D. Mayo Clinic in Arizona
Principal Investigator: Amber L. Isley, M.D. Mayo Clinic in Florida
  More Information

No publications provided

Responsible Party: Aminah Jatoi, M.D., Mayo Clinic Cancer Center Identifier: NCT00936728     History of Changes
Other Study ID Numbers: RC08C6, NCI-2009-01130, R01CA124614, RC08C6, 09-000862
Study First Received: July 6, 2009
Last Updated: March 24, 2014
Health Authority: United States: Federal Government processed this record on November 20, 2014